- Home
- CRVS vs SPOK Comparison
CRVS vs SPOK Comparison
Compare CRVS & SPOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- SPOK
- Stock Information
- Founded
- CRVS 2014
- SPOK 2004
- Country
- CRVS United States
- SPOK United States
- Employees
- CRVS N/A
- SPOK N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- SPOK Telecommunications Equipment
- Sector
- CRVS Health Care
- SPOK Telecommunications
- Exchange
- CRVS Nasdaq
- SPOK Nasdaq
- Market Cap
- CRVS 459.0M
- SPOK 379.1M
- IPO Year
- CRVS 2016
- SPOK 1992
- Fundamental
- Price
- CRVS $5.79
- SPOK $17.47
- Analyst Decision
- CRVS Strong Buy
- SPOK Hold
- Analyst Count
- CRVS 4
- SPOK 1
- Target Price
- CRVS $15.00
- SPOK $15.00
- AVG Volume (30 Days)
- CRVS 547.2K
- SPOK 111.4K
- Earning Date
- CRVS 11-11-2025
- SPOK 10-29-2025
- Dividend Yield
- CRVS N/A
- SPOK 7.15%
- EPS Growth
- CRVS N/A
- SPOK 10.71
- EPS
- CRVS N/A
- SPOK 0.83
- Revenue
- CRVS N/A
- SPOK $140,742,000.00
- Revenue This Year
- CRVS N/A
- SPOK $2.26
- Revenue Next Year
- CRVS N/A
- SPOK $3.69
- P/E Ratio
- CRVS N/A
- SPOK $21.05
- Revenue Growth
- CRVS N/A
- SPOK 1.79
- 52 Week Low
- CRVS $2.54
- SPOK $13.55
- 52 Week High
- CRVS $10.00
- SPOK $19.31
- Technical
- Relative Strength Index (RSI)
- CRVS 56.88
- SPOK 44.78
- Support Level
- CRVS $5.64
- SPOK $17.33
- Resistance Level
- CRVS $6.09
- SPOK $17.64
- Average True Range (ATR)
- CRVS 0.34
- SPOK 0.34
- MACD
- CRVS -0.05
- SPOK -0.05
- Stochastic Oscillator
- CRVS 50.00
- SPOK 31.30
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.